SignalChem is a biotechnology company focused on the research, development and production of innovative cell signaling products to advance basic research and drug discovery efforts, with specific emphasis on the production of highly purified, biologically active, human recombinant proteins.
Cellular signalling or the mechanism by which a cell transmits its signals inwards, ultimately producing a specific biological response, is of fundamental clinical importance. It is well documented that aberrations in these discrete pathways have been linked to the development of a variety of human diseases including cancer, cardiovascular disease, metabolic disorders, neurodegenerative disease and inflammatory conditions amongst others.
With the success of signal transduction inhibitors in the clinic, there is an intensive effort to identify targets linked with the pathogenesis of a human disease and to develop selective molecules to perturb these targets in an effort to improve patient prognosis and minimise the non-specific systemic side-effects associated with generalised treatment modalities.
The founders and scientific members of SignalChem have the knowledge to understand the architecture and biology of these discrete signalling pathways and to leverage this expertise to bring value-added products to the market. SignalChem is emerging as a leader and a key contender in the life science recombinant protein market place.
SignalChem’s core product areas include active human protein kinases, active human protein phosphatases, unactive signalling proteins, assay kits and biologically relevant kinase and phosphatase substrates.